Replies to post #87978 on Biotech Values

[iwfal]

ZGEN Thrombin markets

I asked Tuck if ZGEN would receive a double-digit royalties on ex-US sales of Recothrom as well, but he didn't know. Do you?

Yes, ZGEN has previously said it was tiered up to 20%. But of course all of that is moot now.

OMRI never made a big deal of Evithrom, Evicel was selling much better and the fibrin patch was meant to be the next driver.

I have to say that I don't understand what happened to Recothrom at the EMEA since Evithrom was approved only last year. There could be some clues in there about what it is the EMEA wants for Reco approval - or it could be random regulator behavior.

[DewDiligence]

Apropos to the thrombin/fibrin thread…

Israel Sues J&J Re Biosealant Rights

http://www.reuters.com/article/idCNLDE5BL19Z20091222

›9:56am EST

JERUSALEM, Dec 22 (Reuters) - Israel's government on Tuesday filed a 500 million shekel ($132 million) lawsuit against Omrix Biopharmaceuticals, alleging the company stole its rights to a biological sealant that was developed at a state-run hospital.

Israeli-based Omrix was bought by Johnson & Johnson <JNJ> in late 2008 for $438 million.

The lawsuit agaist Omrix and founder Robert Taub was filed in a Tel Aviv court as a means to protect and recover the government's intellectual properties and patents, Israel's finance and justice ministries said in a joint statement.

Omrix officials were not immediately available for comment.

The sealant, the statement said, is a life-saving product aimed at stopping severe haemorrhaging.

The government said the product was developed by a doctor at a state-run hospital, and as such the rights belong to Israel. Omrix used Sheba Hospital's research and facilities to develop the product and Israel's government partly funded the sealant.

Israel claims that Omrix and Taub made use of state-owned technology without compensating the government. It also said the price Johnson & Johnson's Ethicon unit paid for Omrix was largely based on the value of the allegedly stolen technology.‹